Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced the launch of its XploreRNA™ app for advanced cross-database searches, easy interpretation of data and seamless planning of experiments.
XploreRNA™ allows scientists engaged in transcription analysis to scroll any transcript, view splice sites, SNPs, and to zoom in on specific transcripts of interest in an interactive interface. Major databases including Ensembl, miRBase etc., have been cross-annotated to provide for all-in-one searches. Relevant abstracts and original publications have been integrated through PubMed. Products are automatically customized to address search results and readily ordered.
The body of biological data is growing exponentially which makes it challenging for scientists to stay abreast and benefit from big data. To complicate matters different annotations of major databases make cross-database searches time consuming and complicate the identification of relevant genetic information, e.g. microRNA-mRNA interactions. XploreRNA™ overcomes all of these challenges, and is the first in a series of new apps from Exiqon for scientists in both academia and industry.
XploreRNA™ enables “on-the-fly” discussions based on cross-annotated scientific information that is now made available at your fingertips. Results may be easily shared and converted to studies of relevant gene expressions whether for validation purposes or functional analysis.
“An important value proposition for Exiqon is to guide our customers through experimental data, to reach scientific conclusions and make decisions on how to validate data. The XploreRNA™ app does all of this for our customers and requires no prior knowledge about complicated database searches” says Henrik M. Pfundheller, SVP, Sales and Marketing and continues “Should our customers be interested in conducting further experiments the XploreRNA™ will suggest the relevant customized LNA® enhanced products directly available for ordering”.
XploreRNA™ is currently available on iOS platforms but will soon also be available on Android and Windows platforms.
XploreRNA™ can be downloaded at www.exiqon.com or the App Store:
https://itunes.apple.com/us/app/advanced-molecular-genetics/id871741048?ls=1&mt=8
Additional information:
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
About XploreRNA™
XploreRNA™ cross-annotates major databases containing biological information relevant for transcript analysis. All databases are regularly updated by advanced text mining of the literature referenced through integrated access to PubMed for reading of abstracts and original publications.
XploreRNA™ enables searches across databases and different search terms or identifiers can therefore be used to retrieve the same information. More RNAs can be identified than would be possible for databases searches that are dependent on specific gene identifiers. XploreRNA™ allows for detailed analysis of transcripts in human, mouse and rat.
Search results are presented graphically including validated and predicted microRNA targets as well as both disease and tissue information.
About Exiqon
Exiqon's products are based on the proprietary LNA® technology. This technology offers unique advantages for detection of microRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of microRNA research products for microRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on microRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen.
